Breaking Ground in NASH Treatment: Resmetirom on the Horizon
Development in treatment for patients with non-alcoholic steatohepatitis (NASH).
HUB & Patient Support Solutions Complement Pre-Commercialization Services
AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.
Re-Think. Re-Consider. Re-Calibrate.
2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies
Something for Everyone at Rare Disease Week on Capitol Hill
Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.
AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights
Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.
Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities
Removing barriers to reach Health equity.
Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome
Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.
Update on Gene Therapy and Genome-Editing for Rare Diseases
There’s some upbeat news in gene therapy and genome-editing treatments.
Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients
The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care.